Free Shipping On Orders Over $200 Within Canada!
A new study published in Comprehensive Psychiatry suggests that a moderate 10mg dose of psilocybin therapy may significantly reduce symptoms of obsessive-compulsive disorder (OCD)—without producing the intense psychedelic effects typically associated with higher doses. The findings add to growing evidence that psilocybin, the active compound in magic mushrooms, may have targeted therapeutic benefits beyond depression. This is especially relevant to exploring psilocybin therapy in Canada as researchers seek to understanding its effectiveness in treating various mental health conditions.
Led by researchers at the University of Hertfordshire and Imperial College London, the study involved 19 adults with moderate to severe OCD. Participants first received a very low “placebo-like” dose, followed four weeks later by a 10mg dose of psilocybin. One week after the higher dose, participants showed clinically meaningful reductions in OCD symptoms, particularly in compulsive behaviors, even though intrusive thoughts often remained.
Researchers noted that this moderate-dose approach may be especially important for people with OCD, who often fear loss of control. Unlike high-dose psychedelic experiences, the 10mg dose was well tolerated, with no serious adverse effects and minimal anxiety reported.
The findings also align with growing evidence from both human and animal studies suggesting that psilocybin helps disrupt rigid brain circuits linked to repetitive behaviors. Neurobiological research indicates the compound may weaken maladaptive feedback loops in the brain while strengthening healthier neural pathways—offering a possible explanation for its effect on compulsions.
Importantly, the study found that benefits were temporary, typically lasting about one week, suggesting that psilocybin may work best as part of a broader therapeutic framework rather than a standalone cure. Researchers note that combining moderate doses with behavioral therapies like exposure and response prevention (ERP) could enhance and extend benefits.
While the study was small and further research is needed, it adds to a growing body of evidence supporting psilocybin’s potential role in treating OCD, particularly for patients who do not respond well to conventional medications. As research continues, these findings contribute to a more nuanced understanding of how different doses of psilocybin may target specific mental health conditions—highlighting its promise beyond depression alone.
At Shroom Garden, we are committed to providing a safe option to those who are interested in exploring psilocybin mushrooms online. We offer a variety of products with psilocybin mushrooms. You can choose from psilocybin dried mushrooms, microdose capsules, gummies, or chocolates.
We are committed to promoting the safe and responsible use of our products, which is why we require strict age verification before any purchase is completed. This process ensures that only adults of legal age can access our offerings, in compliance with all relevant laws and regulations. By maintaining these standards, we aim to protect younger individuals from potential harm while fostering a safe environment for informed adult consumers.
Every product we offer undergoes rigorous third-party laboratory testing to verify purity, potency, and dosage accuracy. These tests confirm that each batch is free from harmful contaminants, ensuring that customers receive only the highest-quality products. We make these results available to our consumers as part of our dedication to full transparency and trust.
If you are interested in beginning to explore your psilocybin mushrooms journey with Shroom Garden or exploring psilocybin therapy in Canada, our experienced and professional customer service team is here if you wish to buy magic mushrooms in Canada. We recommend that all of users take the following precautions while using their psilocybin mushrooms products after ordering psilocybin mushrooms products online:
What are you looking for?
